Antibody Mediated Rejection in Liver Transplantation: An Update
April 8 – 9, 2016
The Fairmont Dallas
1717 North Akard StreetDallas, TX 75201 US
A Two-Day Collaboration to Advance AMR in Liver Transplantation
GOALS AND PURPOSE
Acute antibody mediated rejection (AMR) is a well-known and feared entity in solid organ transplants. Some, but not all, previous studies in liver allografts have shown donor specific alloantibodies (DSA) to be detrimental. Mounting evidence has shown the pathologic potential of DSA in liver and simultaneous liver-kidney transplants (SLKT) recipients not only acutely, but also, chronically.
In 2013, we organized a meeting of the minds to define AMR in liver transplantation and forge a path for future research in this burgeoning field. Join us on April 8 through 9, 2016, at the Fairmont Dallas Hotel to follow-up on the outcomes resulting from that conference, review and debate new advances in the field, and further refine the path forward in acute and chronic liver AMR.
WHO SHOULD ATTEND
- Transplant Surgeons
- Transplant Pathologists
- Transplant Hepatologists
- Transplant Nephrologists
- HLA Laboratory Personnel
